研究者情報
検索ページ

（最終更新日：2024-10-09 13:15:17）   ナカジマ　タカコ   NAKAJIMA TAKAKO   中島貴子    所属   医学部医学科 臨床腫瘍学    職種   客員教授

■ 学術雑誌 1. 原著　 Optimizing Organ-Preservation Strategies Through Chemotherapy-Based Selection in Esophageal Squamous Cell Carcinoma: Results From the CROC Multi-Institutional Phase 2 Clinical Trial 2024/06 2. 原著　 Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild-type metastatic colorectal cancer: A phase II trial (HYBRID) 2024/04 3. 原著　 Dexamethasone-sparing on days 2-4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial). 2023/11 4. 原著　 A Phase II Trial of Trifluridine/Tipiracil in Combination with Cetuximab Rechallenge in Patients with RAS Wild-Type mCRC Refractory to Prior Anti-EGFR Antibodies: WJOG8916G Trial. 2023/05 5. 原著　 Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial. 2023/05 6. 原著　 Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors 2022/10 7. 原著　 Genomic Landscape of Primary Tumor Site and Clinical Outcome for Patients with Metastatic Colorectal Cancer Receiving Standard-of-Care Chemotherapy. 2022/05 8. 原著　 Impact of Body Weight Loss on Survival in Patients with Advanced Gastric Cancer Receiving Second-Line Treatment 2022/03 9. 原著　 Real-world effectiveness of nivolumab in advanced gastric cancer: the DELIVER trial (JACCRO GC-08) 2022/01 10. 原著　 Clinical implications of using both fluoropyrimidine and paclitaxel in patients with severe peritoneal metastasis of gastric cancer: A post hoc study of JCOG1108/WJOG7312G 2021/10 11. 原著　 Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer 2021/10 12. 原著　 An observational study on nutrition status in gastric cancer patients receiving ramucirumab plus taxane: BALAST study 2021/04 13. 原著　 Impact of Body Weight Loss on Survival in Patients with Advanced Gastric Cancer Receiving Second-Line Treatment 2021/03 14. 原著　 Multicenter Phase I/II Study of Nivolumab Combined with Paclitaxel Plus Ramucirumab as Second-line Treatment in Patients with Advanced Gastric Cancer 2021/02 15. 原著　 Second-line chemotherapy using taxane in patients with advanced gastric cancer who presented with severe peritoneal metastasis: a multicenter retrospective study 2021/02 16. 総説・解説　 がん化学療法の薬はや調べノート2020・2021年版 2021/02 17. 総説・解説　 がん化学療法の薬はや調べノート2020・2021年版 2021/02 18. 原著　 Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer 2020/12 19. その他　 Study protocol for SPARED trial: randomised non-inferiority phase III trial comparing dexamethasone on day 1 with dexamethasone on days 1–4, combined with neurokinin-1 receptor antagonist, palonosetron and olanzapine (5 mg) in patients receiving cisplatin-based chemotherapy 2020/12 20. 原著　 Clinical practice guidelines for the management of liver metastases from extrahepatic primary cancers 2021 2020/11 21. 症例報告　 Inferior mesenteric arteriovenous fistula during treatment with bevacizumab in colorectal cancer patient: A case report 2020/11 22. 原著　 Early tumor shrinkage and depth of response in the second-line treatment for KRAS exon2 wild-type metastatic colorectal cancer: An exploratory analysis of the randomized phase 2 trial comparing panitumumab and bevacizumab in combination with FOLFIRI (WJOG6210G) 2020/09 23. 総説・解説　 上部消化管がん治療State of the art 2020/06 24. 原著　 Phase I study of the anti-heparin-binding epidermal growth factor-like growth factor antibody U3-1565 with cetuximab in patients with cetuximab- or panitumumab-resistant metastatic colorectal cancer 2020/04 25. 総説・解説　 Recent Developments of Systemic Chemotherapy for Gastric Cancer 2020/04 26. 原著　 Randomized phase II/III study of 5‑fluorouracil/l‑leucovorin versus 5‑fluorouracil/l‑leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108/WJOG7312G). 2020/02 27. 総説・解説　 分子標的治療　消化器がんにおける分子標的治療薬 2020/02 28. 原著　 Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer. 2019/10 29. 総説・解説　 がん治療におけるPatient-Reported Outcome 2019/10 30. 総説・解説　 消化器障害 2019/10 31. 原著　 Analysis of fistula formation of T4 esophageal cancer patients treated by chemoradiotherapy. 2019/09 32. 原著　 Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer. 2019/09 33. 原著　 DELIVER (JACCRO GC-08) Trial: Discover Novel Host-Related Immune-Biomarkers for Nivolumab in Advanced Gastric Cancer 2019/07 34. 原著　 Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study. 2019/07 35. 原著　 Clinical Implications of Decreased Computed Tomography Value after Ramucirumab in Advanced Gastric Cancer 2019/06 36. 原著　 Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. 2019/06 37. 原著　 Multicenter phase II study of trastuzumab with S‑1 plus oxaliplatin for chemotherapy‑naïve, HER2‑positive advanced gastric cancer 2019/05 38. 総説・解説　 Targeting EGFR and RAS/RAF Signaling in the Treatment of Metastatic Colorectal Cancer: From Current Treatment Strategies to Future Perspectives. 2019/04 39. 総説・解説　 後方ライン治療におけるICのポイント 2019/04 40. 総説・解説　 肝機能障害への対応 2019/04 41. 原著　 A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2) 2019/03 42. 原著　 Co-operative groups in the development of chemotherapy for gastric cancer. (Review Article (Invited)) 2019/03 43. 原著　 Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study. 2019/03 44. 原著　 Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer. 2019/03 45. 原著　 Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. 2019/01 46. 原著　 Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Annals of Oncology 30: 34–43, 2019 doi:10.1093/annonc/mdy498 2019/01 47. 症例報告　 Esophagogastric varices were diagnosed in a non-cirrhotic liver case during long-term follow-up after oxaliplatin-based chemotherapy 2018/12 48. 総説・解説　 後方ライン治療におけるICのポイント 2018/11 49. 総説・解説　 疾患別に学ぼう！ 9消化器癌 2018/11 50. 総説・解説　 薬物療法によってフレイル状態に陥りやすい高齢がん患者への対応 2018/11 51. 総説・解説　 免疫療法 2018/09 52. 総説・解説　 消化器（口内炎、食欲不振、悪心嘔吐、下痢脱水） 2018/09 53. その他　 Rationale and design of the TRUSTY study: a randomised, multicentre, open-label phase II/III study of trifluridine/tipiracil plus bevacizumab versus irinotecan, fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following first-line oxaliplatin-based chemotherapy. 2018/08 54. 総説・解説　 Pan-Asian adapted ESMO consensus guidelineの概要 2018/07 55. 総説・解説　 クリニカルシークエンスを基にした分子標的治療の展開 2018/07 56. 総説・解説　 抗体薬　ラムシルマブ、アフリベルセプト 2018/06 57. 総説・解説　 胃癌・RAM(単剤, RAM+PTX) 2018/06 58. 総説・解説　 胃癌化学療法におけるチーム医療の取り組み 2018/06 59. 原著　 Reply to L. Celio et al 2018/05 60. 総説・解説　 がん化学療法の薬はや調べノート2019・2020年版 2018/05 61. 総説・解説　 がん化学療法の薬はや調べノート2019・2020年版 2018/05 62. 原著　 "Placebo-Controlled, Double-Blinded Phase III Study Comparing Dexamethasone on Day 1 With Dexamethasone on Days 1 to 3 With Combined Neurokinin-1 Receptor Antagonist and Palonosetron in High-Emetogenic Chemotherapy" 2018/04 63. 症例報告　 胃癌術後肝転移再発に対してS-1+CDDPおよびS-1療法が奏功した1例 2018/04 64. 原著　 Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2016 for the Clinical Practice of Hereditary Colorectal Cancer (Translated Version) 2018/03 65. 総説・解説　 切除不能進行・再発胃癌に対する1次治療について 2018/03 66. その他　 Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. 2018/02 67. 原著　 Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. 2018/01 68. 総説・解説　 肝機能障害への対応 2018 69. 原著　 Early morphological change for predicting outcome in metastatic colorectal cancer after regorafenib 2017/12 70. 原著　 がん患者の終末期医療における看取り場所の聴取後の在宅がん緩和医療移行の実態 2017/12 71. 原著　 "Early morphological change for predicting outcome in metastatic colorectal cancer after regorafenib" 2017/11 72. 総説・解説　 Profile of trifluridine/tipiracil hydrochloride in the treatment of metastatic colorectal cancer: efficacy, safety, and place in therapy 2017/09 73. 総説・解説　 ①進行大腸がんの一次治療でFOLFOXIRI療法を用いる場合の注意点、②大腸癌の分子標的治療薬の作用機序の違いを考慮した治療戦略の進め方、③分子標的治療に伴う有害事象とその対応 (骨髄抑制、発熱性好中球減少症) 2017/09 74. 総説・解説　 免疫チェックポイント阻害薬　副作用対策チームの実践 2017/09 75. 総説・解説　 切除不能・再発進行胃がんの治療戦略 state-of-art 2017/07 76. 総説・解説　 GOLD試験(胃がん2次治療におけるweekly paclitaxel±olaparib) 2017/06 77. 総説・解説　 JCOG1108/WJOG7312G高度腹水を伴うまたは経口摂取不能の腹膜転移を有する胃癌に対する5-FU/l-LV療法 vs FLTAX (5-FU/l-LV/PTX)療法のランダム化第II/III相比較試験 2017/06 78. 総説・解説　 化学療法のレジメン講座 2017/06 79. 総説・解説　 胃癌RAM (単剤、PTX+RAM) 2017/06 80. 総説・解説　 StageⅣ大腸癌に対する治療戦略：日本と欧米の比較 2017/05 81. 原著　 Phase II study of cetuximab with irinotecan for KRAS wild-type colorectal cancer in Japanese patients. 2017/04 82. 原著　 Dose-escalation study for the targeting of CD44v+ cancer stem cells by sulfasalazine in patients with advanced gastric cancer (EPOC1205). 2017/03 83. 総説・解説　 Cancer Board 2017/02 84. 原著　 Identification of FGFR3-TACC3 fusion in esophageal cancer 2017/02 85. 総説・解説　 切除不能進行胃癌初回化学療法レジメンの選択法. 2017/02 86. 総説・解説　 胃癌化学療法の選択のポイント：術後補助化学療法 2017/02 87. 原著　 Significance of FGF9 Gene in Resistance to Anti-EGFR Therapies Targeting Colorectal Cancer:A Subset of Colorectal Cancer Patients With FgF9 Upregulation May Be Resistant to Anti-EGFR Therapies 2017/01 88. 総説・解説　 がん化学療法の薬　はや調べノート2017-2018年版 2017/01 89. 総説・解説　 がん化学療法の薬　はや調べノート2017-2018年版 2017/01 90. その他　 大腸癌治療ガイドライン 2016/11 91. その他　 遺伝性大腸癌診療ガイドライン 2016/11 92. 原著　 Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G) 2016/08 93. 総説・解説　 大腸がんについての臨床的概論 2016/07 94. 総説・解説　 消化管がん化学療法2016「2. 切除不能・再発胃がんの新薬・バイオマーカー開発の現状と展望」 2016/07 95. 原著　 Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G) 2016/05 96. 原著　 Infusion site adverse events in breast cancer patients receiving highly emetic chemotherapy with prophylactic anti-emetic treatment with aprepitant and fosaprepitant: A retrospective comparison. 2016/04 97. 総説・解説　 胃がん 1) ファーストラインの選択 (S-1+CDDP療法のエビデンスと実際) 2016/04 98. 原著　 Phase I/II study of nab‐paclitaxel plus gemcitabine for chemotherapy‐naive Japanese patients with metastatic pancreatic cancer 2016/03 99. 原著　 Significance of FGF9 gene in resistance to anti-EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti-EGFR therapies. 2016/02 100. 原著　 S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial 2016/01 101. 総説・解説　 1. CQ3 チーム医療 を円滑に行うための工夫は？ 2015/12 102. 総説・解説　 1. CQ4 がん薬物治 療施行にあたって、患者指導をどう進めるか 2015/12 103. 総説・解説　 分子標的薬を用いた個別化治療に必要なバイオマーカー 2015/10 104. 総説・解説　 切除不能進行・再発胃がんに対する一次治療選択の仕方. 2015/10 105. 総説・解説　 胃がんにおけるrilotumumabのランダム化第Ⅱ相臨床試験とRilomet試験の失敗 2015/08 106. 総説・解説　 胃がんに対する分子標的治療 2015/08 107. 原著　 EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition. 2015/07 108. 原著　 Predictability of the anti-tumor efficacy of cetuximab plus irinotecan based on skin rash severity according to observation period in patients with metastatic colorectal cancer after fluorouracil, irinotecan, and oxaliplatin failure 2015/04 109. 総説・解説　 患者さんへの説明・インフォームドコンセントの基本 2015/03 110. 総説・解説　 手足症候群・皮膚障害のマネジメント 2015/03 111. 総説・解説　 経口抗がん薬に関する治療戦略と時流 2015/02 112. 総説・解説　 胃がん、切除不能再発 2015/02 113. 原著　 Predictability of the anti-tumor efficacy of cetuximab plus irinotecan based on skin rash severity according to observation period in patients with metastatic colorectal cancer after fluorouracil, irinotecan, and oxaliplatin failure 2015/01 114. 総説・解説　 Ⅱ副作用別対策「皮膚障害・手足症候群」 2015/01 115. 原著　 A Phase I/II Study of XELIRI Plus Bevacizumab as Second-Line Chemotherapy for Japanese Patients With Metastatic Colorectal Cancer (BIX Study). 2014/10 116. 総説・解説　 消化器（口内炎、食欲不振、悪心嘔吐、下痢脱水） 2014/09 117. 原著　 The Feasibility of a Short Bevacizumab Infusion in Patients with Metastatic Colorectal Cancer. 2014/08 118. 総説・解説　 がん外来化学療法のリアル 2014/07 119. 総説・解説　 抗EGFR抗体薬の副作用、マネージメントの実際 2014/07 120. 総説・解説　 胃がん 2014/05 121. 総説・解説　 副作用と症状マネジメント 2014/04 122. 原著　 Comparison of advanced adenocarcinomas of esophagogastric junction and distal stomach in Japanese patients. 2014/01 123. 総説・解説　 最新胃癌学　一次治療、二次治療のレジメン選択 2014/01 124. 総説・解説　 ML18147試験 2013/12 125. 総説・解説　 がん薬物治療専門医のための模擬テスト41-解答と解説- 2013/11 126. 原著　 Phase II Study of Concurrent Chemoradiotherapy at the Dose of 50.4 Gy with Elective Nodal Irradiation for Stage II-III Esophageal Carcinoma. 2013/06 127. 総説・解説　 胃癌腹膜転移に対する標準治療とは 2013/06 128. 総説・解説　 切除不能・再発胃癌に対する分子標的薬の導入 2013/03 129. 原著　 Lack of association of proteinuria and clinical outcome in patients with bevacizumab for metastatic colorectal cancer. 2013/01 130. 総説・解説　 切除不能・再発大腸がんに対する二次治療以降のエビデンス 2012/12 131. 総説・解説　 腹膜播種症例に対する治療の最近の動向と治療選択 2012/11 132. 総説・解説　 進行大腸がんに対するbevacizumab beyond progressionの評価 2012/10 133. 総説・解説　 食道がん化学療法に用いられるレジメン 2012/10 134. 原著　 Multicenter feasibility study of combination therapy with fluorouracil,leucovorin and paclitaxel(FLTAX)for peritoneal disseminated gastric cancer with massive ascites or inadequate oral intake. 2012/07 135. 原著　 Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLIFIRI in colorectal cancer with liver metastasis. 2012/05 136. 総説・解説　 分子標的治療薬による血栓塞栓症 2012/03 137. 総説・解説　 胃癌術後補助化学療法におけるDIF 2012/03 138. 総説・解説　 抗体治療 2011/12 139. 総説・解説　 消化器癌の個別化治療におけるバイオマーカーの現状と展望 2011/12 140. 総説・解説　 胃癌化学療法個別化は可能か 2011/06 141. 総説・解説　 FGFR阻害剤 2011/05 142. 総説・解説　 最新の抗悪性腫瘍薬併用療法　分子標的治療薬の役割-ベバシズマブを含む併用化学療法　大腸がん、肺癌- 2011/05 143. 総説・解説　 食道癌の化学療法-進行度別の標準治療はなにか？ 2011/05 144. 原著　 Current status and problems of molecular target therapy for colorectal cancer. 2011/01 145. 総説・解説　 大腸癌に対する分子標的療法の現状と問題点 2011/01 146. 総説・解説　 がん診療の考え方・進め方-患者と向きあうための基礎知識「消化器がん患者を診る」 2010/10 147. 総説・解説　 【外来癌化学療法の現状と進歩】新規分子標的薬剤・支持療法の外来導入「シスプラチンを含むレジメン；胃癌」 2010/06 148. 総説・解説　 レジデントからのQ&A「殺細胞性抗癌剤と分子標的薬の違いについて教えてください」 2010/06 5件表示 全件表示(148件)

■ 著書 1. 部分執筆　 疾患別に学ぼう!　消化器がん「ヘルスケアプロバイダーのためのがん・生殖医療」 2019/04 2. 編集・監修　 薬がみえる vol.3 第1版「薬がみえる vol.3 第1版」 2016/11 3. 部分執筆　 胃がん「新臨床腫瘍学改訂第3版」 2012/12 4. その他　 進行胃癌で治癒切除後補助化学療法を施行していたが、術後１年後に中等量の腹水を伴う腹膜転移再発をきたし、化学療法を施行した症例「症例から学ぶメディカルオンコロジー」 2011/11 5. その他　 各臓器がんの最新標準治療　２）胃がん「腫瘍内科」 2011/10 6. その他　 うまく続ける　消化管がん化学療法「消化器BOOKS」 2011/01 7. その他　 臨床医が感じるコンパニオン診断薬の有用性～大腸がん治療での遺伝子検査、抗がん剤治療を例として～「個別化医療の世界的動向を踏まえた開発・事業戦略」 2011/01 5件表示 全件表示(7件)

■ 学会発表 1. TRUSTY試験における血管新生関連遺伝子とFTD/TPI+BEVの有効性の検討 （口頭発表） 2022/10 2. Final analysis of clinical outcomes in the DELIVER trial: Observational study of nivolumab treatment in advanced gastric cancer (JACCRO GC-08). （ポスター） 2022/09 3. がんの日常診療におけるePROによる症状モニタリングの有用性の評価および、有害事象とQoLの実態に関するレジストリ研究（RegiPRO study） （ポスター） 2022/06/19 4. An observational study of health-related quality of life (HRQoL) with electronic patient-reported outcome (ePRO) monitoring during nivolumab therapy for advanced gastric cancer as the 3rd or later line treatment: NIVO-G QoL study. （ポスター） 2022/06 5. Symptom monitoring and its digitalization at daily cancer chemotherapy in Japan: a nation-wide multi-stakeholder survey. （口頭発表，一般） 2022/02/19 6. Exploratory analysis of baseline tumor burden in the TRUSTY study: Phase 2/3 study of 2nd-line FTD/TPI + BEV for mCRC. （口頭発表） 2022/02 7. Host-related biomarkers including gut microbiome to predict toxicities of nivolumab in advanced gastric cancer: DELIVER trial (JACCRO GC-08).  2022/01/22 8. Exploratory analysis of baseline tumor burden in the TRUSTY study: A randomized phase 2/3 study of trifluridine/tipiracil plus bevacizumab versus irinotecan and fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer. （ポスター） 2022/01 9. Genomic factors of gut microbiome associated with patient characteristics in gastric cancer: from the DELIVER trial (JACCRO GC-08)  2021/10/23 10. Placebo-controlled, double-blinded phase Ⅲ study comparing dexamethasone on day 1 with dexamethasone on days 1 to 4, with combined neurokinin-1 receptor antagonist, palonosetron, and olanzapine in patients receiving cisplatin-containing highly emetogenic chemotherapy: SPARED Trial  2021/09/17 11. Gut microbiome to predict survival time in advanced gastric cancer treated with nivolumab: the DELIVER trial (JACCRO GC-08) （口頭発表，一般） 2021/07/03 12. A multicenter phase II trial of trifluridine/thipiracil in combination with cetuximab in RAS wild-type metastatic colorectal cancer patients refractory to prior anti-EGFR antibody : the WJOG8916G trial  2021/06/30 13. Gene alterations in ctDNA related to the resistance mechanism of anti-EGFR antibodies and clinical efficacy outcomes of anti-EGFR antibody rechallenge plus trifluridine/tipiracil in metastatic colorectal cancer patients in WJOG8916G trial  2021/06/30 14. The Implication of Neurofilament light chain and Galectin-3 in paclitaxel-induced peripheral neurotoxicity for patients with advanced gastric cancer  2021/06/24 15. The Implication of Neurofilament light chain and Galectin-3 in paclitaxel-induced peripheral neurotoxicity for patients with advanced gastric cancer  2021/05/29 16. A phase I/II trial of trifluridine/tipiracil in combination with irinotecan in patients with advanced gastric cancer refractory to fluoropyrimidine, platinum, and taxane.  2021/02/19 17. Gene profiling of circulating tumor DNA (ctDNA) in RAS wild-type mCRC patients who are refractory to anti-EGFR antibody  2021/02/19 18. A phase I/II trial of trifluridine/tipiracil in combination with irinotecan in patients with advanced gastric cancer refractory to fluoropyrimidine, platinum, and taxane. （ポスター） 2021/01/15 19. Genomic pathway of gut microbiome to predict efficacy of nivolumab in advanced gastric cancer: DELIVER trial (JACCRO GC-08)  2021/01/15 20. 104P Angiogenesis-related factors and clinical outcomes in combination therapy with paclitaxel (PTX), ramucirumab (RAM) plus nivolumab (Nivo) for advanced gastric cancer (AGC)  2020/09/20 21. 血管新生阻害薬による化学療法中に下腸間膜動静脈瘻を合併した大腸癌症例 （ポスター，一般） 2020/08/11 22. 「がんと診断されたときからの緩和ケア」の推進に関わる厚生労働行政への提言の策定 （口頭発表，シンポジウム・ワークショップ・パネルディスカッション等） 2020/08/09 23. がん診断時からの緩和ケアを提供するための患者のアンメットニーズに関する研究 （口頭発表，シンポジウム・ワークショップ・パネルディスカッション等） 2020/08/09 24. Feasibility of TAS-118+oxsliplation as perioperaive chemotherapy for gastric cancer （口頭発表，シンポジウム・ワークショップ・パネルディスカッション等） 2020/07/01 25. Updated analysis of DELIVER trial (JACCRO GC-08): A large observational/translational study of nivolumab treatment in advanced gastric cancer  2020/07/01 26. Tumor response and growth rate of nivolumab treatment in advanced gastric cancer: real-world data from a large observational/translational study, JACCRO GC-08 (DELIVER trial) （ポスター） 2020/05/29 27. A phase I/II study of nivolumab, paclitaxel, and ramucirumab as second-line in advanced gastric cancer. （ポスター） 2020/01/24 28. Analysis of early tumor shrinkage (ETS) and depth of response (DpR) in metastatic colorectal cancer (mCRC) patients (pts) treated with second-line FOLFIRI plus panitumumab (Pani) or bevacizumab (Bev): Results from a randomized phase II WJOG6210G trial.  2020/01/24 29. The treatment strategy of the second-line chemotherapy for metastatic colorectal cancer (mCRC) patients (pts) with early progression in the first-line chemotherapy with bevacizumab (BEV), BEV beyond progression (BBP), or non-BBP.  2020/01/24 30. Feasibility and pathological response of TAS-118 + oxaliolation as perioperative chemotherapy for patients with lovally advanced gastric cancer(APOLLO-11) （ポスター，一般） 2020/01/23 31. A phase I/II trial of trifluridine/tipiracil in combination with irinotecan in patients with advanced gastric cancer refractory to fluoropyrimidine, platinum, and taxane.  2020/01/15 32. Identification of Site-specific Genome Alterations in Metastatic Colorectal Cancer: Sub-study 003 of the SCRUM-Japan GI-SCREEN.  2019/10/26 33. Association of gastric acid suppression with efficacy of immune checkpoint inhibitors (ICIs) in advanced cancer patients （口頭発表） 2019/10/24 34. International clinical practivce guideline for metastatic liver tumor: Chmotherapy （口頭発表） 2019/10/24 35. がん腫別に考える体重減少とその要因：胃癌 （口頭発表） 2019/10/24 36. Interim analysis of an observational/translational study for nivolumab treatment in advanced gastric cancer: JACCRO GC-08 (DELIVER trial) （口頭発表） 2019/09/29 37. Has vcure become a realistic goal for metastatic cancer? （口頭発表） 2019/09/26 38. KN  2019/09/19 39. Call-to- Action for METAvivor 〜ABCC会議からの提案〜 （口頭発表，シンポジウム・ワークショップ・パネルディスカッション等） 2019/09/07 40. in advanced solid cancer patients （口頭発表） 2019/09 41. Association of gastric acid suppression with efficacy of immune checkpoint inhibitors （口頭発表） 2019/07/20 42. 私の腫瘍内科医としてのキャリア：大学病院の立場から  2019/07/20 43. Prospective study to investigate the clinical efficacy of G-CSF for Docetaxel + Cisplatin + 5-Fluorouracil (DCF) chemotherapy in patients with esophageal squamous cell carcinoma (ESCC) （口頭発表） 2019/07/18 44. Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as the second-line treatment in patients with advanced gastric cancer  2019/07 45. Phase I Safety and Pharmacokinetic Study of KN035, the first subcutaneously administered, novel fusion Anti-PD-L1 Antibody in Japanese Patients with Advanced Solid Tumors.  2019/06/01 46. Phase III Study of Comparing Dexamethasone on Day 1 with Day 1-4 with Combined Nurokinin-1 Receptor Antagonist, Palonosetron and Olanzapine in Cisplatin-based Chemotherapy:SPARED Trial  2019/06 47. A phase II study of Trastuzumab with S-1 plus Oxaliplatin for HER2-positive advanced gastric cancer (HIGHSOX).  2019/03/08 48. 胃がん栄養 （ポスター） 2019/03/08 49. A phase II study of Trastuzumab with S-1 plus Oxaliplatin for HER2-positive advanced gastric cancer (HIGHSOX)  2019/03/01 50. 患者アドボカシーワークショップ （口頭発表） 2019/03/01 51. 最新の胃癌治療戦略〜IOによる変革 （口頭発表） 2019/03/01 52. 高度腹膜転移胃癌に対する5-FU/l-LV療法vs. FLTAX（5-FU/l-LV+PTX)療法のランダム化第II/III相比較試験 （口頭発表，シンポジウム・ワークショップ・パネルディスカッション等） 2019/03/01 53. Perspectives of postoperative chemotherapy for gastric cancer: From Asian point of view. （口頭発表） 2019/02/28 54. 胃がん治療戦略〜アンメットメディカルニーズにどう対応するか〜 （口頭発表） 2019/02/28 55. 胃癌における免疫療法 最新のエビデンスを実臨床で活かすには （口頭発表） 2019/02/28 56. Randomized phase II/III study of 5-fluorouracil /l-leucovorin vs. 5-fluorouracil /l-leucovorin plus paclitaxel in gastric cancer with severe peritoneal metastasis (JCOG1108/WJOG7312G). American Society of Clinical Oncology, Gastrointestinal Cancer Symposium 2019 poster presentation （ポスター） 2019/01/17 57. Identification of site-specific genome alterations in metastatic colorectal cancer: Sub-study 003 of the SCRUM-Japan GI-SCREEN  2019/01 58. A translational study to discover novel host-related immune-biomarkers for nivolumab (Nivo) in advanced gastric cancer (GC): JACCRO GC-08 (DELIVER trial) （ポスター） 2018/12/14 59. Case presentation Metastatic oeso-gastric cancer WHY we need an Asian guideline for oeso-gastric cancer? （口頭発表） 2018/11/24 60. 大腸癌化学療法〜Basic and New〜 （口頭発表，特別・招待講演等） 2018/11/18 61. Perspectives and attitudes toward the integration of oncology and palliative care in Japan: Qualitative analysis of a nationwide survey.  2018/11/16 62. Current status of the integration of oncology and palliative care in Japan: A nationwide survey. （ポスター） 2018/10/22 63. Perspectives and attitudes towards the integration of oncology and palliative care in Japan: A nationwide survey. （ポスター） 2018/10/22 64. A phase II study of Trastuzumab with S-1 plus Oxaliplatin for HER2-positive advanced gastric cancer (HIGHSOX). （ポスター） 2018/10/21 65. Antibiotics may enhance the efficacy of gemcitabine treatment for advanced pancreatic cancer （ポスター） 2018/10/21 66. BIG BANG study: A Multicenter Phase II Study of the MEK Inhibitor Binimetinib + BRAF Inhibitor Encorafenib +Anti-EGFR Antibody Cetuximab in Patients with BRAF Non-V600E Mutated Metastatic Colorectal Cancer (EPOC 1703). （ポスター） 2018/10/21 67. BRAVERY study: A multicenter phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer (EPOC1701). （ポスター） 2018/10/21 68. Dynamic change of immune-related gene expression status during chemoradiotherapy in locally advanced esophageal cancer （ポスター） 2018/10/20 69. 高齢がん患者の薬物療法における最適なマネージメントを目指して. （口頭発表，シンポジウム・ワークショップ・パネルディスカッション等） 2018/10/18 70. Role of patient reported outcome (PRO) in supporitve/palliateive care trial? （口頭発表，シンポジウム・ワークショップ・パネルディスカッション等） 2018/08/31 71. Regorafenib療法のラーニングカーブ評価 （ポスター） 2018/07/20 72. フッ化ピリミジン不応・不耐の高度腹膜転移を伴う胃癌に対するタキサンを用いた二次治療の有効性・安全性の検討 （ポスター） 2018/07/20 73. An investigator initiated multicenter phase I/II study of paclitaxel, ramucirumab with nivolumab as the second-line treatment in patients with metastatic gastric cancer. （ポスター） 2018/06 74. Phase I study of the anti-heparin binding-EGF antibody U3-1565 with cetuximab in patients with cetuximab- or panitumumab-resistant metastatic colorectal cancer （ポスター） 2018/04 75. Randomized phase II/III study of FL vs. FLTAX in gastric cancer with severe peritoneal metastasis (JCOG1108/WJOG7312G) （口頭発表） 2018/03/01 76. Fluoropyrimidine (F) alone versus F plus platinum (P) as 1st-line chemotherapy in patients (pts) with advanced gastric cancer (AGC) and severe peritoneal metastasis (SPM): A multicenter observational study.  2018/01 77. A feasibility study of TAS-118 plus Oxaliplatin as perioperative chemotherapy for locally advanced gastric cancer. poster presentation  2017/09/08 78. The Nationwide Cancer Genome Screening Project in Japan SCRUM-Japan GI-SCREEN: Efficient Identification of Cancer Genome Alterations in Advanced Pancreatic Cancer.  2017/09/08 79. Clinical Implication of Morphological Changes of Ramucirumab in Metastatic Gastric Cancer  2017/07/27 80. Development of new agents for unresectable gastric cancer: Global?Asian?Japanese?  2017/07/27 81. Newest knowledge in perioperative chemotherapy for gastric cancer especially around TAS-118.  2017/07/27 82. Early morphologic change (EMC) caused by regorafenib (REGO) in patients (pts) with metastatic colorectal cancer (mCRC) （一般） 2017/07 83. 胃癌術後肝転移再発に対してS-1+CDDP及びS-1療法が奏功した１例 （口頭発表，一般） 2017/06/23 84. What are the barriers to and facilitators for the implementation of early palliative care in Japan? （口頭発表，シンポジウム・ワークショップ・パネルディスカッション等） 2017/06/22 85. Identification of a FGFR3-TACC3 fusion in esophageal cancer  2017/04/01 86. Development of new treatments and clinical practice for gastric cancer with peritoneal metastasis. （シンポジウム・ワークショップ・パネルディスカッション等） 2017/03 87. A phase II study of ziv-aflibercept (Z) + FOLFIRI in Japanese patients (pts) with metastatic colorectal cancer (mCRC).  2017/01 88. A GASTRIC CANCER PATIENT WITH PERITONEAL INFILTRATION, ASCITES, LOW SERUM ALBUMIN LEVELS AND POSITIVE HBc ANTIBODY HAS POTENTIALLY AND INDICATION FOR CHEMOTHERAPY  2016/12 89. 抗EGFR抗体のbest use 〜皮膚障害対策を含めて （特別・招待講演等） 2016/10/01 90. 大腸癌ガイドライン 医師用 2016年版改定案について （口頭発表） 2016/10 91. 随伴症状の改善が必要と考えられる患者さんへの治療戦略 （口頭発表，シンポジウム・ワークショップ・パネルディスカッション等） 2016/10 92. 高度催吐性がん化学療法に対するNK1受容体拮抗薬+パロノセトロン+デキサメタゾン（DEX）day1-3 ｖｓ day1の多施設共同第3相試験 （ポスター） 2016/09/19 93. 聖マリアンナ医科大学臨床研究データセンターの現状 （口頭発表，一般） 2016/09/03 94. MSI-status and Cancer-Related Genome Alterations in advanced colorectal cancer (CRC) (GI-SCREEN 2013-01-CRC sub-study) （口頭発表，シンポジウム・ワークショップ・パネルディスカッション等） 2016/07/29 95. Phase III study comparing dexamethasone on day1 to on day1-3 with NK₁ receptor antagonist and palonosetoron in HEC  2016/07/29 96. 当院のIO副作用対策チームの取り組み （シンポジウム・ワークショップ・パネルディスカッション等） 2016/07/29 97. 腫瘍内科医はどのようなところで必要とされているのか？（消化器腫瘍内科医の立場） （シンポジウム・ワークショップ・パネルディスカッション等） 2016/07/29 98. 切除不能進行・再発大腸癌に対するサルベージライン化学療法（regorafenib, TAS102）の後方視的検討 （口頭発表，一般） 2016/07/28 99. The Nationwide Cancer Genome Screening Project for Gastrointestinal Cancer in Japan (GI-SCREEN): MSI-status and Cancer-Related Genome Alterations in advanced colorectal cancer (CRC) (GI-SCREEN 2013-01-CRC sub-study).  2016/06 100. HER2陽性切除不能進行再発胃癌に対するSOX+Trastuzumab併用療法の第II相臨床試験(中間解析)  2016/03 101. 聖マリアンナ医科大学病院におけるシスプラチンによる腎障害の実態と軽減対策の効果  2016/03 102. 切除不能進行・再発膵癌患者におけるnab-paclitaxel+ Gem療法第I/II相試験:追加解析  2015/10 103. 教育講演「胃癌」 （特別・招待講演等） 2015/10 104. Fibroblast growth factor 9 gene amplification can induce resistance to anti-EGFR therapy in colorectal cancer  2015/09 105. Impact of worsening in patient reported symptomatic adverse events (AEs) on deterioration of daily assessed quality of life (QOL) in cancer patients receiving initial chemotherapy; prospective exploratory study  2015/09 106. Randomized phase II study of S-1 plus oral leucovorin (SL) versus SL plus oxaliplatin (SOL) versus S-1 plus cisplatin (SP) in patients with advanced gastric cancer (AGC): Update data  2015/09 107. Stage Ⅳ胃癌に対する化学療法後 conversion surgery の治療成績 （ポスター，一般） 2015/07/15 108. "Fibroblast Growth Factor 9 gene amplification can induce resistance to anti-EGFR therapy in colorectal cancer "  2015/07 109. EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition.  2015/07 110. T4食道癌の瘻孔形成における臨床経過について  2015/07 111. 切除不能進行・再発膵癌患者に対するnab-Paclitaxel+ Gemcitabine療法第I/II相試験：追加解析  2015/07 112. 初回化学療法例における日々の患者報告アウトカム(patient reported outcome)に基づく 自覚的副作用の悪化によるQOLへの影響  2015/07 113. 化学療法・抗リウマチ治療におけるB型肝炎ウィルス再活性化予防への取り組み  2015/07 114. 外来化学療法における発熱性好中球減少症の一症例  2015/07 115. 遠隔転移を有する進行食道扁平上皮癌に対する化学放射線療法の経口摂取改善における臨床的意義  2015/07 116. STAS-Jを用いた、当院緩和ケアチーム活動の検討 （ポスター，一般） 2015/06/20 117. STAS-Jを用いた、当院緩和ケアチーム活動の検討 （ポスター，一般） 2015/06 118. Phase II trial of Concurrent Chemoradiotherapy at the Dose of 50.4 Gy with Elective Nodal Irradiation for clinical stage II/III Esophageal Cancer  2015/05 119. The Nationwide Cancer Genome Screening Projects for Gastrointestinal Cancer in Japan(SCRUM-Japan GI-SCREEN): Efficient identification of actionable cancer genome alterations in advanced colorectal and non-colorectal gastrointestinal cancer (GI Screen 2013-01-CRC and 2015-01-Non CRC)  2015/05 120. 当院における胃癌患者に対する多職種による治療の実際 （口頭発表，シンポジウム・ワークショップ・パネルディスカッション等） 2015/03/06 121. "The Nationwide Genomic Screening Project for Gastrointestinal Cancer in Japan (GI-SCREEN): Simultaneous Identification of KRAS, NRAS, BRAF and PIK3CA Mutation in Advanced Colorectal Cancer (aCRC) (GI-SCREEN 2013-01)"  2015/01 122. Efficacy, Safety and Pharmacokinetics of Weekly nab-Paclitaxel Plus Gemcitabine in Japanese Patients With Metastatic Pancreatic Cancer (MPC) : Phase I/ II Trial  2014/11 123. Randomized phase II study of S-1 plus oral leucovorin (SL) versus SL plus oxaliplatin (SOL) versus S-1 plus cisplatin (SP) in patients with advanced gastric cancer (AGC): Updated Overall Survival Data  2014/09 124. Effect of sulfasalazine (SSZ) on cancer stem-like cells (CSCs) via inhibiting xCT signal pathway: Phase 1 study in patients with gastric cancer (EPOC 1205).  2014/07/17 125. がん患者の看取る場所についての検討：在宅診療に移行した患者が、病院に再入院する理由を中心に  2014/07/17 126. 切除不能進行・再発膵癌患者に対する ABI-007+ Gemcitabine 療法第 I/II 相試験.  2014/07/17 127. 臨床病期II/III食道癌に対するmRTOG臨床第II相試験におけるSalvage手術症例の検討  2014/07/03 128. Effect of sulfasalazine (SSZ) on cancer stem-like cells (CSCs) via inhibiting xCT signal pathway: Phase 1 study in patients with gastric cancer (EPOC 1205)  2014/04/05 129. Safety, Tolerability, and Pharmacokinetics of Rilotumumab Combined With Cisplatin and Capecitabine in Japanese Patients With MET-Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma  2014/04/05 130. Sulfasalazine (SSZ) works cancer stem-like cells (CSCs) via inhibiting xCT signal pathway: Phase 1 study in patients with gastric cancer (EPOC 1205)  2014/04/05 131. WS3: 高度腹水/経口摂取不能の腹膜転移胃癌に対する5-FU/l-LV vs FLTAX療法のランダム化第II/III相比較試験  2014/03/20 132. New anticancer agent for gastric cancer  2013/12/16 133. 集学的治療により骨転移出現後も長期生存している進行肝内胆管癌の１例 （口頭発表，一般） 2013/11/21 134. Anti-HER2 therapy for Anti-HER2 therapy for gastric cancer: how should we maximize?  2013/08/29 135. 教育セミナーBセッション：胃癌 （特別・招待講演等） 2013/08/29 136. 臨床病期II/III食道癌に対する50.4 Gy、5-FU+CDDP併用化学放射線療法の臨床第II相試験  2013/06/13 137. 「化学療法」〜全身化学療法の基本. 教育講演3, 2013 （特別・招待講演等） 2013/05/16 138. 胃癌化学療法における個別化医療の可能性  2013/03 139. Perspectives of postoperative chemotherapy for resectable gastric cancer  2013/02 140. Perspaective of first-line chemotherapy for advanced gastric cancer （口頭発表，一般） 2012/10 141. 直腸癌CASE DISCUSSION  2011/09/15 142. 再発胃がん及び高度腹膜播種例の治療戦略  2011/07/21 143. 化学療法の緩和治療における在宅支援の実態  2011/07/21 144. 外来経口抗がん剤治療における薬剤師による介入の検討  2011/07/21 145. 未治療進行胃癌に対するcediranibとシスプラチン及びフッ化ピリミジン(TS-1又はカペシタビン)併用の第Ⅰ相臨床試験  2011/07/21 146. 医師が期待するチーム医療における薬剤師の役割  2011/06/11 5件表示 全件表示(146件)